Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day

2020-06-09
Presentation
Webcast

CEO Magnus Corfitzen presented the company at ABGSC Life Science Summit Day and Redeye Orphan Drug Day. Link to the video presentations our found below.

ABGSC: https://youtu.be/KNRDLYkbooE

Redeye: https://www.redeye.se/video/event-presentation/786947/ascelia-pharma-ceo-magnus-corfitzen-presents-at-orphan-drugs-may-27

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral and Oncoral – currently under development.Mangoral is a novel contrast agent for MR-scans, currently in the pivotal Phase 3 clinical study SPARKLE. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases or primary tumours) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase 2 for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com

2020-06-30

Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has, based on the authorisat ...
2020-06-09

Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day

2020-05-20

Updated SPARKLE timelines due to Covid-19 impact

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma”) today announced updated timelines for the completion and top line results of the pivotal Phase 3 study SPARKLE with the lead compound Mangoral, which are now expected in H2 2021 instead of H1 2021 as previously communicated. The expected addition of three to six months reflects the impact of the Covid-19 pandemic.